Valeant Pharmaceuticals International, Inc. (NYSE: VRX) shares faded 4% to $23.50, on positive vibes from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for latanoprostene bunod ophthalmic solution, 0.024%, an intraocular pressure lowering single-agent eye drop for patients with open angle glaucoma or ocular hypertension. Share volume was 6.9 million, compared to an all-day average of 31.1 million
